MannKind mentioned in article on Ariad...
Company
Drugs in Development Pipeline
Average Analyst Share-Price Target
TTM R&D Spending
Ariad |
4 |
$19.13 |
$89 million |
Vivus |
1 |
$30.18 |
$26 million |
MannKind (Nasdaq: MNKD ) |
4 |
$5.20 |
$93 million |
Human Genome Sciences (Nasdaq: HGSI ) |
7 |
$13.64 |
$151 million |
Sources: Yahoo! Finance, Morningstar, and S&P Capital IQ.
Each company has its blockbuster in waiting. Ariad has ponatinib; Vivus has its anti-obesity treatment Qnexa, which already received a glowing 20-2 recommendation for approval from an FDA advisory committee; MannKind is working on inhaled-insulin treatment Afrezza; and Human Genome Sciences has lupus treatment Benlysta, which seems to be so appealing that it's attracted a buyout offer from partner GlaxoSmithKline. Each of these drugs should reach approval (or rejection) stage within a year at the most, so it may not take too long for investors to find out just how valuable they really are.
http://www.fool.com/investing/high-growth/2012/06/19/how-high-can-ariad-fly.aspx